Navigation Links
New guidelines for treating rheumatoid arthritis
Date:7/22/2008

BIRMINGHAM, Ala. Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB).

Lead author Kenneth Saag, M.D., M.Sc., a professor in the UAB Division of Clinical Immunology and Rheumatology, said the new guidelines update strategies for treating RA with the goal of preventing joint damage and disability.

The new recommendations do not strive to replace individualized medical decisions, Saag said. Instead, they are meant to guide rheumatologists and other health care workers toward the most updated recommendations. The last set of American College of Rheumatology RA treatment guidelines was published in 2002.

"The recommendations developed are not intended to be used in a 'cookbook' or prescriptive manner, or to limit a physician's clinical judgment," Saag said. "They provide guidance based on clinical evidence and expert panel input."

The recommendations focus on several classes of anti-arthritic drugs, including a potent group of agents called disease-modifying anti-rheumatic drugs (DMARDs). Newer genetically engineered DMARDs called biologics often work in combination with earlier therapies. Many anti-arthritic drugs are designed to stop damaging inflammation, and biologics work to interrupt the chain of events that leads to inflammation.

Newer biologics called anti-TNF agents adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade) prevent the production of an immunity protein that plays a role in inflammation.

Some of the key recommendations include:

  • Methotrexate or leflunomide therapy is recommended for most RA patients.
  • Anti-TNF agents etanercept, infliximab, or adalimumab along with methotrexate can be used in new or early
    '/>"/>

Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

Page: 1 2

Related biology news :

1. NHLBI issues first US von Willebrand Disease clinical practice guidelines
2. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
3. 2 carotid artery stenting studies show results comparable to AHA guidelines
4. UNC study questions FDA genetic-screening guidelines for cancer drug
5. Tumor-inhibiting protein could be effective in treating leukemia
6. Hebrew University develops novel approach for treating mitochondrial disorders
7. Treating chronic pain, migraine & muscle spasticity through inhibition of neurotransmitter glutamate
8. Environmental epigenetics has potential for preventing and treating disease
9. International scientists tackle obstacles to treating brain disorders
10. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
11. Massive microRNA scan uncovers leads to treating muscle degeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... of scientists led by Fred Hutchinson Cancer Research Center ... feasibility of large-scale, standardized protein measurements, which are necessary ... The study, to be published Dec. 8 online in ... scientists, targeted protein-detection approach has the potential to systematically ...
... even a mild traumatic brain injury. While the brain may ... suggest that the brain,s protective coverings may feel the ... mouse trauma model, senior author Dorian McGavern, Ph.D., scientist at ... of the National Institutes of Health, watched specific cells mount ...
... Philadelphia have manipulated key biological events in adult blood ... after the newborn period. Because this fetal hemoglobin is ... (SCD), the cell culture findings may open the door ... "Our study shows the power of a ...
Cached Biology News:Novel method could help bring cancer biomarkers to clinic 2Novel method could help bring cancer biomarkers to clinic 3Concussion secrets unveiled in mice and people 2Concussion secrets unveiled in mice and people 3Flipping a gene switch reactivates fetal hemoglobin, may reverse sickle cell disease 2
(Date:11/26/2014)... The Alliance for Safe Biologic ... European physicians at the "1 ST EuropaBio ... at the Spanish Ministry of Health, Social Services ... the Spanish Bioindustry Association (ASEBIO), included regulators from ... oncology and rheumatology societies, representatives from a hospital ...
(Date:11/26/2014)... 2014 Whitehouse Laboratories is pleased ... Morris County (New Jersey) Chamber of Commerce as ... business organization in the North Jersey area, offers ... some key clients in the pharmaceutical and biotechnology ... area. Membership enables Whitehouse Laboratories a higher level ...
(Date:11/26/2014)... PA (PRWEB) November 25, 2014 The ... of its official conference and exposition mobile app, ... for free download in the App Store for iOS ... a valuable resource tool before, during and after the ... containing details on exhibiting companies, technical sessions, Conferee Networking ...
(Date:11/26/2014)... N.J. and WILMINGTON, DE (PRWEB) November 26, 2014 ... 2nd Annual MPN Heroes recognition reception on December 5, ... of Hematology’s annual meeting. The MPN Heroes event will ... contributions in the field of myeloproliferative neoplasms (MPNs). ... show "Nashville," will discuss his family's cancer journey at ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4
... Omaxe Infrastructure &,Construction Private Ltd(OICPL), a wholly owned subsidiary ... the construction of Allopathic Medical,College and Associated Hospital at ... value of the project is Rs250 crores,approx., The ... with total built up area,of 15.66 lac sq ft. ...
... initial listing requirements with NASDAQ; Stock Symbol ... extends cash runway while focusing on ... 21 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals, Inc. (formerly Sonus ... announced that the Company has completed its ...
... SHANGHAI, China, Aug. 21 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, ... "the,Company"), a leading Chinese firm specializing ... distribution of probiotics products,today announced it ... Square,Pharmaceutical Co., Ltd. ("Square Pharmaceutical") to ...
Cached Biology Technology:Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores 2Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 2Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 3Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 4Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 5Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 6China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 2China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 3
Anti-MD-2 (IN) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
p-Bcl-2 (Thr 74)...
Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
CBF-B (G-2)...
Biology Products: